Andres Forero-Torres

Summary

Affiliation: University of Alabama at Birmingham
Country: USA

Publications

  1. doi request reprint A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma
    Andres Forero-Torres
    University of Alabama at Birmingham, Comprehensive Cancer Center, 1824 Sixth Avenue South, Birmingham, AL 35294 3300, USA
    Br J Haematol 146:171-9. 2009
  2. doi request reprint Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma
    Andres Forero-Torres
    University of Alabama at Birmingham, Birmingham, AL 35294 3300, USA
    Leuk Lymphoma 54:277-83. 2013
  3. pmc Brentuximab vedotin in transplant-naive patients with relapsed or refractory hodgkin lymphoma: analysis of two phase I studies
    Andres Forero-Torres
    Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama 35294 3300, USA
    Oncologist 17:1073-80. 2012
  4. ncbi request reprint A novel monoclonal antibody design for radioimmunotherapy
    Andres Forero
    Department of Medicine, Division of Hematology Oncology, Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA
    Cancer Biother Radiopharm 18:751-9. 2003
  5. ncbi request reprint A phase I study of an anti-GD3 monoclonal antibody, KW-2871, in patients with metastatic melanoma
    Andres Forero
    Department of Medicine, Division of Hematology Oncology, University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL 35294 3300, USA
    Cancer Biother Radiopharm 21:561-8. 2006
  6. ncbi request reprint Pretargeted radioimmunotherapy (RIT) with a novel anti-TAG-72 fusion protein
    Andres Forero-Torres
    Departments of Medicine, Division of Hematology Oncology University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL 35294 3300, USA
    Cancer Biother Radiopharm 20:379-90. 2005
  7. ncbi request reprint Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma
    Andres Forero
    University of Alabama at Birmingham Comprehensive Cancer Center, 35294 3300, USA
    Blood 104:227-36. 2004
  8. doi request reprint Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor-positive breast cancer
    Andres Forero-Torres
    Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL 35294 3300, USA
    Clin Breast Cancer 10:275-80. 2010
  9. doi request reprint Phase I study of a modified regimen of ⁹⁰Yttrium-ibritumomab tiuxetan for relapsed or refractory follicular or transformed CD20+ non-Hodgkin lymphoma
    Christos Vaklavas
    Department of Hematology and Oncology, Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    Cancer Biother Radiopharm 28:370-9. 2013
  10. pmc Basal-like breast cancer stem cells are sensitive to anti-DR5 mediated cytotoxicity
    Angelina I Londoño-Joshi
    Department of Molecular and Cellular Pathology, University of Alabama at Birmingham, Birmingham, AL 35294 2182, USA
    Breast Cancer Res Treat 133:437-45. 2012

Research Grants

  1. Radioimmunotherapy: An Anti-Neoplastic Strategy
    Andres Forero; Fiscal Year: 2006

Detail Information

Publications18

  1. doi request reprint A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma
    Andres Forero-Torres
    University of Alabama at Birmingham, Comprehensive Cancer Center, 1824 Sixth Avenue South, Birmingham, AL 35294 3300, USA
    Br J Haematol 146:171-9. 2009
    ..These results demonstrate that weekly administration of SGN-30 is safe, with modest clinical activity in patients with ALCL...
  2. doi request reprint Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma
    Andres Forero-Torres
    University of Alabama at Birmingham, Birmingham, AL 35294 3300, USA
    Leuk Lymphoma 54:277-83. 2013
    ..Dacetuzumab-related grade 3/4 adverse events occurred infrequently. Six of 30 evaluable patients achieved a complete response (CR) and eight a partial response (PR) per investigator assessment for an overall response rate (ORR) of 47%...
  3. pmc Brentuximab vedotin in transplant-naive patients with relapsed or refractory hodgkin lymphoma: analysis of two phase I studies
    Andres Forero-Torres
    Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama 35294 3300, USA
    Oncologist 17:1073-80. 2012
    ..The objective of this post-hoc analysis was to characterize the safety and efficacy of brentuximab vedotin for patients with relapsed or refractory HL who refused or were ineligible for ASCT...
  4. ncbi request reprint A novel monoclonal antibody design for radioimmunotherapy
    Andres Forero
    Department of Medicine, Division of Hematology Oncology, Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA
    Cancer Biother Radiopharm 18:751-9. 2003
    ..These studies support the further clinical investigation of this agent in phase I trials by intravenous and intraperitoneal routes...
  5. ncbi request reprint A phase I study of an anti-GD3 monoclonal antibody, KW-2871, in patients with metastatic melanoma
    Andres Forero
    Department of Medicine, Division of Hematology Oncology, University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL 35294 3300, USA
    Cancer Biother Radiopharm 21:561-8. 2006
    ..KW-2871 (IgG1 kappa chimeric antibody) targets GD3, which is upregulated in melanomas. We conducted a phase I trial of KW-2871 in patients with metastatic melanoma...
  6. ncbi request reprint Pretargeted radioimmunotherapy (RIT) with a novel anti-TAG-72 fusion protein
    Andres Forero-Torres
    Departments of Medicine, Division of Hematology Oncology University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL 35294 3300, USA
    Cancer Biother Radiopharm 20:379-90. 2005
    ..CC49Fusion protein performs well in a pretargeted RIT schema, and further study with escalating doses of (90)Y should be pursued. This strategy has the potential to deliver effective radiation tumor doses to TAG- 72+ tumors...
  7. ncbi request reprint Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma
    Andres Forero
    University of Alabama at Birmingham Comprehensive Cancer Center, 35294 3300, USA
    Blood 104:227-36. 2004
    ..B9E9FP performs well as the targeting component of PRIT with encouraging dosimetry, safety, and efficacy. A dose escalation trial of (90)Y-DOTA-biotin in this format is warranted...
  8. doi request reprint Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor-positive breast cancer
    Andres Forero-Torres
    Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL 35294 3300, USA
    Clin Breast Cancer 10:275-80. 2010
    ....
  9. doi request reprint Phase I study of a modified regimen of ⁹⁰Yttrium-ibritumomab tiuxetan for relapsed or refractory follicular or transformed CD20+ non-Hodgkin lymphoma
    Christos Vaklavas
    Department of Hematology and Oncology, Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    Cancer Biother Radiopharm 28:370-9. 2013
    ..3 and 10.9 months, respectively. Although this regimen was associated with a high response rate, the hematologic toxicity was higher than with the standard ⁹⁰Y-ibritumomab tiuxetan regimen...
  10. pmc Basal-like breast cancer stem cells are sensitive to anti-DR5 mediated cytotoxicity
    Angelina I Londoño-Joshi
    Department of Molecular and Cellular Pathology, University of Alabama at Birmingham, Birmingham, AL 35294 2182, USA
    Breast Cancer Res Treat 133:437-45. 2012
    ..TRA-8 exposure to 2LMP and SUM159 BrCSC preparations produced significant inhibition of tumorigenicity. DR5 maybe a therapeutic target on the surface of basal-like BrCSC which is amenable to agonistic monoclonal anti-DR5 therapy...
  11. pmc Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5)
    Andres Forero-Torres
    University of Alabama at Birmingham, Comprehensive Cancer Center, Birmingham, Alabama 35294 3300, USA
    Cancer Biother Radiopharm 25:13-9. 2010
    ..It has demonstrated cytotoxicity in vitro and in vivo antitumor efficacy to a wide range of solid tumors in murine xenograft models. Tigatuzumab is a humanized IgG1 monoclonal antibody derived from TRA-8...
  12. doi request reprint How do I treat "triple-negative" disease
    Christos Vaklavas
    Comprehensive Cancer Center, University of Alabama at Birmingham, AL 35294 3300, USA
    Curr Treat Options Oncol 12:369-88. 2011
    ....
  13. ncbi request reprint TRAIL-receptor antibodies as a potential cancer treatment
    Donald J Buchsbaum
    Department of Radiation Oncology, Division of Radiation Biology, 1530 3rd Avenue South, WT1 674, Birmingham, AL 35294 6832, USA
    Future Oncol 3:405-9. 2007
    ....
  14. doi request reprint A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia
    Richard R Furman
    Division of Hematology Oncology, Weill Cornell Medical College, New York, NY 10065, USA
    Leuk Lymphoma 51:228-35. 2010
    ..This modest single-agent activity may warrant further testing of dacetuzumab in combination with other chronic lymphocytic leukemia therapies...
  15. ncbi request reprint Bendamustine in non-Hodgkin lymphoma: the double-agent that came from the Cold War
    Andres Forero-Torres
    Department of Medicine, Division of Hematology and Oncology, University of Alabama at Birmingham, AL, USA
    Clin Lymphoma Myeloma 8:S13-7. 2007
    ..This article provides a review of studies using bendamustine in the treatment of non-Hodgkin lymphomas...
  16. ncbi request reprint Diffuse F-18 FDG uptake in skeletal muscles secondary to chills resulting from sepsis: a cause for underestimation of viable tumor
    Buddhiwardhan Ojha
    Division of Nuclear Medicine, University of Alabama at Birmingham, Alabama 35249 6830, USA
    Clin Nucl Med 29:600-1. 2004
  17. pmc Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma
    Christos Vaklavas
    Division of Hematology Oncology, Comprehensive Cancer Center, University of Alabama at Birmingham, AL, USA
    Ther Adv Hematol 3:209-25. 2012
    ..Herein, we review the biology of CD30 and brentuximab vedotin, and the clinical data that has accumulated thus far with SGN-35...
  18. doi request reprint Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcγRIIIa-genotyped patients with previously treated follicular lymphoma
    Andres Forero-Torres
    University of Alabama at Birmingham, Birmingham, Alabama, USA
    Clin Cancer Res 18:1395-403. 2012
    ..Safety, pharmacokinetics, and efficacy were assessed in a phase 1/2 trial in patients with previously treated follicular lymphoma (FL)...

Research Grants1

  1. Radioimmunotherapy: An Anti-Neoplastic Strategy
    Andres Forero; Fiscal Year: 2006
    ..The follow-up trial will be a phase II study to determine the efficacy of 131I-HuCC49ACH2 in resistant/refractory EOC patients. ..